logo
  Join        Login             Stock Quote

Omeros (OMER) Starts Planned Pharmacokinetic Substudy In OMS302 Phase 3 Program

 May 31, 2012 09:37 AM


(By Balaseshan) Omeros Corp. (NASDAQ:OMER), a clinical-stage biopharmaceutical company, said it has started the planned pharmacokinetic substudy in its Phase 3 clinical program evaluating OMS302 in patients undergoing intraocular lens replacement (ILR) surgery.

The company is conducting the pharmacokinetic (PK) substudy to confirm the low levels of systemic exposure previously observed in preclinical studies of the drug product. OMS302 is being developed for use during intraocular lens replacement (ILR) surgery, including cataract surgery and refractive lens exchange.

Blood samples will be collected prior to and during the first 24 hours after surgery from each of twelve OMS302- and placebo-treated patients in the ongoing second OMS302 Phase 3 clinical trial. These data will be included in Omeros' OMS302 marketing applications in the United States and the European Union.

[Related -Stocks End Sharply Lower Amid 'Fiscal Cliff' Fears; HP (HPQ) Falls]

In the first Phase 3 clinical trial of OMS302, the drug product demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis and reduction of postoperative pain.

Omeros is now conducting the second Phase 3 clinical trial, which is expected to enroll about 400 patients. This trial will evaluate the same efficacy and safety measures as the earlier successful Phase 2b and Phase 3 clinical trials.

The company remains on track to announce data from its second Phase 3 OMS302 clinical trial in the second half of 2012 and, assuming positive results, to file both an NDA and MAA in the first part of 2013.

[Related -Analysts' Rating And Target Changes: BCDS, CMI, DAL, OMER]

OMS302, one of Omeros' proprietary PharmacoSurgery products, is added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain.

The company's recent discussions with U.S. and E.U. regulators confirmed its expectations that this 24-patient substudy should provide sufficient PK data for its OMS302 marketing applications.

OMER closed Wednesday's regular session up 0.10% at $10. The stock has been trading between $3.16 and $10.88 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageDelta Air Lines (DAL): Panic Selling Makes This Airline Stock Ripe For A Quick Pop

If there ever were a teaching moment in the stock market, it was this week. Earnings, trendlines and read on...

article imageInvesting In The Time Of Ebola

Volatility is back in the market. Whether we are being tossed and turned by the Ebola crisis, Russian read on...

article imageMarket Volatility Continues But Is Bottom In?

The market’s volatility continues, and it has the outlook and expectations of the financial media jumping read on...

article imageBrazil's Petrobras Attracts Bullish Options Play

Brazilian stocks advanced with ADR shares in state-owned oil company Petroleo Brasileiro SA (Ticker: PBR) read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.